Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Annamaria Rauco"'
Autor:
Francesco Pantano, Matteo Santoni, Giuseppe Procopio, Mimma Rizzo, Roberto Iacovelli, Camillo Porta, Alessandro Conti, Antonio Lugini, Michele Milella, Luca Galli, Cinzia Ortega, Francesco Maria Guida, Marianna Silletta, Giovanni Schinzari, Elena Verzoni, Daniela Modica, Pierfilippo Crucitti, Annamaria Rauco, Alessandra Felici, Valentina Ballatore, Stefano Cascinu, Giuseppe Tonini, Giacomo Carteni, Antonio Russo, Daniele Santini
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0120427 (2015)
Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum chol
Externí odkaz:
https://doaj.org/article/0ead798f347c420a8b9a691e710c04be
Autor:
Alain Gelibter, Fabio Calabrò, Enzo Maria Ruggeri, Maria Bassanelli, Daniele Santini, Marco Russano, Silvana Giacinti, Diana Giannarelli, Viola Barucca, Fabiana Letizia Cecere, Annamaria Rauco, Emilio Bria, Maria Rita Migliorino, Anna Ceribelli
Publikováno v:
Journal of Clinical Oncology. 37:e14075-e14075
e14075 Background: Unlike chemotherapy, the optimum treatment duration with Immune checkpoint inhibitors (ICIs) is not clearly established. The aim of this study was to assess the outcome of patients (pts) who discontinued immune-based therapies for
Autor:
Marco Montanaro, Luca Maurillo, Ambra Di Veroli, Barbara Anaclerico, Roberto Ricci, Elena Rossi, Atelda Romano, Luca Petriccione, Valerio De Stefano, Roberto Latagliata, Annamaria Rauco, Giuliana Alimena, Nicoletta Villivà, Elisabetta Abruzzese, Ada D'Addosio, Massimo Breccia, Alessandro Andriani, Cristina Santoro, Cinzia De Gregoris, Malgorzata Monika Trawinska, Antonia Centra, Sabrina Crescenzi Leonetti, Marianna De Muro
Background Thrombotic episodes are the major complication in the follow-up of Philadelphia negative Myeloproliferative Neoplasms (MPN), with high morbidity and mortality, as reported in several retrospective studies. At present, however, few prospect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cc106d28d36bc748ccccb03844e99e9
http://hdl.handle.net/11573/987310
http://hdl.handle.net/11573/987310
Autor:
Annamaria Rauco, Roberta Martiniani, Stefano Ascani, Fabrizio Liberati, Cristina Zannori, Angelo Genua, Anna Marina Liberati
Background. BV, an anti-CD30 antibody-drug conjugate, has been approved for the treatment of Hodgkin lymphoma (HL) and ALCL. Of interest, BV has shown activity in PTCLs other than ALCL that express low or even undetectable levels of CD30. In particul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::888ab738dcdd54e0829eb32c074c4747
http://hdl.handle.net/11391/1406587
http://hdl.handle.net/11391/1406587
Autor:
Lorenzo Falchi, Fabrizio Liberati, Daniela Capello, Annamaria Rauco, Roberta Pace, Vincenzo Capparella, Barbara Palumbo, Michele Cianciulli, Anna Marina Liberati, Rita Emili
Publikováno v:
European Journal of Haematology
We report the case of an Epstein-Barr virus (EBV)- and human immunodeficiency virus-serum negative patient suffering from repeatedly relapsing classical Hodgkin’s Lymphoma (cHL) associated with a histological picture of plasma cell-hyaline vascular
Autor:
Marianna Silletta, Annamaria Rauco, Alessandra Felici, Antonio Russo, Luca Galli, Giuseppe Procopio, Antonio Lugini, Elena Verzoni, Daniele Santini, Pierfilippo Crucitti, Alessandro Conti, Mimma Rizzo, Daniela Modica, Stefano Cascinu, Giuseppe Tonini, Camillo Porta, Giacomo Cartenì, Cinzia Ortega, Francesco Pantano, Roberto Iacovelli, Valentina Ballatore, Giovanni Schinzari, Matteo Santoni, Michele Milella, Francesco Maria Guida
Publikováno v:
PLoS ONE
PLoS ONE, Vol 10, Iss 4, p e0120427 (2015)
PLoS ONE, Vol 10, Iss 4, p e0120427 (2015)
Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of tota
Autor:
Barbara Anaclerico, Cristina Santoro, Giuseppe Avvisati, Roberto Ricci, Francesco Buccisano, Ambra Di Veroli, Roberto Latagliata, Marianna De Muro, Elena Rossi, Malgorzata Monika Trawinska, Ada D'Addosio, Massimo Breccia, Nicoletta Villivà, Marco Montanaro, Luca Petriccione, Antonio Spadea, Elisabetta Abruzzese, Annamaria Rauco, Giuseppe Cimino, Michele Cedrone, Atelda Romano, Sabrina Leonetti Crescenzi, Alessandro Andriani, Giuliana Alimena, Valerio De Stefano
Publikováno v:
Blood. 128:5473-5473
Background: MPNs including Polycythemia Vera (PV), Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF), are clonal hematopoietic diseases in which the discovery of molecular driver mutations (JAK2, CALR, MPL) has deeply modified diagnostic
Autor:
Roberta Pace, Annamaria Rauco, Lorenzo Falchi, Emilio Donti, Debora Luzi, Viola Festuccia, Anna Marina Liberati, Rita Emili, M. Schippa, Carmela Ardisia, Emilia Giugliano
Introduction Progressive improvement has been observed in CKR and survival of CML patients (pts) in response to interferon (IFN)a-based regimens, or imatinib. The purpose of this study is the evaluation of: rate of, time to and duration of CKR in acc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4961858115b6d7cc06e3e394024d467f
http://hdl.handle.net/11391/1018267
http://hdl.handle.net/11391/1018267
Autor:
Emilio Donti, Annamaria Rauco, Roberta Pace, M. Schippa, Enrico Gottardi, Debora Luzi, Alessandra Bassetti, Giuseppe Saglio, Anna Marina Liberati, Rosanna Capozzi
Publikováno v:
Blood. 106:4872-4872
Introduction: Continous improving results have been obtained during last two decades in the control of Ph’positive chronic myeloid leukemia(CML). However the final goal of molecular remission remains difficult to obtain even in the STI age. Aims :
Autor:
Roberta Pace, Fabrizio Liberati, Rosanna Capozzi, Annamaria Rauco, Vincenzo Capparella, Maria G. Morandi, Anna Marina Liberati, Michele Cianciulli
Publikováno v:
Blood. 106:4824-4824
Background: CD is a rare entity characterized by unicentric or multicentric clinical presentation. Three histologic variants (hyline vascular, plasmacell and mixed) have been described. Coexistence of CD and non-Hodgkin (NHL) and Hodgkin’s (HL) lym